Finanzen von cbdMD Inc (YCBD)YCBDcbdMD Inc

cbdMD Inc (YCBD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is E-commerce sales, accounting for 67.3% of total sales, equivalent to $3.80M. Another important revenue stream is Wholesale sales. Understanding this composition is critical for investors evaluating how YCBD navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, cbdMD Inc maintains a gross margin of 53.29%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13.64%, while the net margin is -14.15%. These profitability ratios, combined with a Return on Equity (ROE) of -62.55%, provide a clear picture of how effectively YCBD converts its operational activities into shareholder value.

In the context of the broader market, YCBD competes directly with industry leaders such as PMCB and ENVB. With a market capitalization of $5.55M, it holds a significant position in the sector. When comparing efficiency, YCBD's gross margin of 53.29% stands against PMCB's N/A and ENVB's N/A. Such benchmarking helps identify whether cbdMD Inc is trading at a premium or discount relative to its financial performance.

cbdMD has shown some improvement in gross margin, currently at 53.29%, but continues to report net losses, with a net income of -$876,783 in Q2 2026. Revenue for Q2 2026 was $5.64 million, indicating a positive trend, but overall profitability remains a concern.